StocksMedium•5 November 2026•
1 min read
Annovis Bio Prices $21 Million Public Offering to Fund Neurodegenerative Therapy
Key Facts
1Annovis Bio announced the pricing of a public offering of common stock and pre-funded warrants to raise $21 million.
Annovis Bio announced the pricing of a public offering of common stock and pre-funded warrants to raise $21 million. GlobeNewswire reported that the offering consists of 19 million shares of common stock and warrants for an additional 21 million shares, intended to provide capital for the company's clinical-stage operations.
The company plans to use the proceeds to fund the development of buntanetap, an investigational therapy for Alzheimer's and Parkinson's diseases. ANVS closed at $1.21 on November 4, 2026, prior to the announcement of the offering which typically exerts downward pressure on share prices due to dilution.